1. Agenda Item Title: FACULTY HIRE ABOVE SALARY SCHEDULE, UNSOM.

2. BACKGROUND & POLICY CONTEXT OF ISSUE:
   Board of Regents approval is required for faculty hires when the employment salary exceeds the maximum amount on the salary schedule. UNSOM requests such approval for the appointment of Christian Stone, M.D. as Associate Professor, Gastroenterology, in the Department of Internal Medicine, Las Vegas, University of Nevada School of Medicine (UNSOM).

3. SPECIFIC ACTIONS BEING RECOMMENDED OR REQUESTED:
   President Milton D. Glick requests approval of employment salary above schedule for Christian Stone, M.D., in the position of Associate Professor, Gastroenterology, Internal Medicine, Las Vegas, UNSOM, at a salary of $417,000, which exceeds the established maximum salary of $219,452. Dr. Stone’s salary will be derived from a combination of funding: (a) University Medical Center (UMC); (b) clinical practice revenues; (c) CMS funds; and (d) state funds.

4. IMPETUS (WHY NOW?):
   In light of the recent closures of several endoscopy centers in Southern Nevada, there is a great need for additional practitioners to perform these procedures. UNSOM is committed to partnering with (UMC) to provide and enhance the quantity and quality of these critical services that are currently provided to the residents of Southern Nevada. An exceptionally qualified, fellowship-trained candidate has been identified and is willing to accept this position.

   The Department of Internal Medicine has recently hired its first gastroenterologist and he will begin working upon completion of Nevada licensure and credentialing. The Department needs two more gastroenterologists with which to establish a division of gastroenterology. Historically, gastroenterologists have been very difficult to recruit, as the private sector is far more lucrative. With all of the recent problems with the local endoscopy centers, the establishment of a division of gastroenterology within UNSOM and having Dr. Stone as a faculty member will help restore confidence to the residents of Southern Nevada.

   Additionally, a division of gastroenterology will offer not only medical student and resident training within the school but will also be the foundation for a fellowship program to be able to retain UNSOM residents within the system and keep them practicing in Nevada once they have completed their training. The addition of Dr. Stone will greatly enhance the department’s residency program training in this critical sub-specialty.

   The current search has identified an exceptionally qualified candidate, Christian Stone, M.D., who is fellowship trained and board certified in gastroenterology.

   UMC has committed annual salary support of 45%, with the remaining to be derived from clinical practice revenues (26%), CMS funds (19%), and state funds (10%). If UMC removes funding for this position, Dr. Stone’s salary will be reduced per his offer letter.

5. BULLET POINTS TO SUPPORT REQUEST/RECOMMENDATION:
   - Dr. Stone has demonstrated the proven clinical ability to assume this position.
   - UMC is committing the majority of the salary.
   - Having a fellowship trained gastroenterologist as a faculty member of UNSOM is invaluable in reassuring the community that all proper Infection Control procedures are being complied with.
   - The number of fellowship trained gastroenterologists is decreasing, and it is becoming more difficult to recruit for an academic position, as the private sector is far more lucrative. UNSOM competes in a different market economy than other professional schools and relies extensively on robust industry benchmarks to set competitive salaries in order to attract the best individuals for the job.
   - With the relatively low number of practitioners in relation to the population of Las Vegas, it is
anticipated that this can be a profit center for the department and the UNSOM.

6. POTENTIAL ARGUMENTS AGAINST THE REQUEST/RECOMMENDATION:
Physicians and other medical school faculty should be compensated at levels similar to other professors and faculty.

7. ALTERNATIVE(S) TO WHAT IS BEING REQUESTED/RECOMMENDED:
Hire a more junior and less accomplished individual with compensation within Q2.

8. COMPLIANCE WITH BOARD POLICY:

- Consistent With Current Board Policy: Title #_____ Chapter #_____ Section #_____
- Amends Current Board Policy: Title #_____ Chapter #_____ Section #_____
- Amends Current Procedures & Guidelines Manual: Chapter #_____ Section #_____
- Other: Title #2 Chapter 5 Section # 5.4.1.; 5.5.2 (Seeking exception to salary schedule)
- Fiscal Impact: Yes __X____ No_____

Explain: Dr. Stone’s salary will be derived from a combination of funding. UMC has committed annual salary support of 45%, with the remaining to be derived from clinical practice revenues (26%), CMS funds (19%), and state funds (10%). If UMC removes funding for this position, Dr. Stone’s salary will be reduced per his offer letter.
# 2007 ~ 2008

**Academic Faculty**

**Medicine -- M.D.s**

**Supplemental Salary Schedule**

## 12 Months

<table>
<thead>
<tr>
<th>RANK</th>
<th>MINIMUM</th>
<th>Q1</th>
<th>Median (Q2)</th>
<th>Q3</th>
<th>Maximum</th>
</tr>
</thead>
<tbody>
<tr>
<td>PROFESSOR</td>
<td>IV</td>
<td>142,138</td>
<td>167,221</td>
<td>172,509</td>
<td>242,026</td>
</tr>
<tr>
<td>ASSOCIATE PROFESSOR</td>
<td>III</td>
<td>119,041</td>
<td>140,048</td>
<td>159,910</td>
<td>190,828</td>
</tr>
<tr>
<td>ASSISTANT PROFESSOR</td>
<td>II</td>
<td>101,434</td>
<td>119,334</td>
<td>137,373</td>
<td>160,195</td>
</tr>
<tr>
<td>INSTRUCTOR</td>
<td>I</td>
<td>85,251</td>
<td>100,295</td>
<td>122,408</td>
<td>140,179</td>
</tr>
</tbody>
</table>

For employees subject to the employer-paid retirement plan, the amounts shown are reduced as provided by law (currently .91012).

The use of the medical salary schedules is dependent upon the ability of the faculty member to generate enough funds to support his/her salary through patient care. If the faculty member is in a position that does not generate sufficient funds to support his/her salary, the general academic faculty salary schedules may be used for that reason alone.
April 30, 2010

Dr. Christian Stone
2839 St. Rose Pkwy.
Henderson, NV 89052

Dear Dr. Stone,

We are pleased to make this conditional offer of employment to you for the position of Associate Professor in the Department of Internal Medicine at the University of Nevada School of Medicine. Your duties will include:

- Providing consultative and procedural care for patients at University Medical Center (UMC), in the faculty practice, and other sites as identified by the Chair and Division Chief
- Supervising and educating resident physicians and students on the gastroenterology rotation
- Lecturing on gastroenterology topics in the residency’s core curriculum lecture series, conferences, morning report, and the student clerkship lecture series
- Assisting the Department Chair in the creation of a Division of Gastroenterology
- Develop a program of scholarly activity

The starting date for this non-tenure track position at 1.0 FTE will be determined after the Department receives verification that you have obtained a Nevada medical license, and you have been credentialed at the designated entities and malpractice coverage has been obtained.

Your salary will be $417,000.00 per annum, contingent upon UMC funding. Please be advised that this salary is contingent on endorsement from the Provost and President of the University of Nevada, Reno, and formal approval by the Nevada Higher System of Education (NSHE) Board of Regents.

Your compensation for the first year (first twelve months) will include four components:

1) $180,500.00 from University Medical Center (subject to soft funding clause)*
2) $115,500.00 from clinical compensation. Please note that salary derived from clinical compensation depends upon your net clinical revenue and the availability of funds in our department’s account with University Health System (UHS) and may be changed quarterly during the year (see Section 1 of the Member Practice Agreement.)
3) $80,000.00 CMS funds and
4) $41,000.00 from state funds

Initial here _____
*Soft Funding Clause
Notwithstanding any provision of the NSHE Code, including but not limited to Section 5.9.1., if, in the best judgment of the supervisor, with approval of the appointing authority, funds for this position are no longer available or must be directed to other purposes, your contract may be terminated or notice of non-reappointment to employment may be given with 30 days notice.

The Administration reserves the right to change your sources of funding in the future.

At this time, your appointment is to be considered as conditional since a firm offer of employment is contingent upon your meeting the applicable requirements designated below:

(i) Possessing and maintaining a Nevada medical license. Providing an official transcript of your professional degree(s) and/or a letter from the Nevada State Board of Medical Examiners stating that you are in “good standing”.

(ii) The School of Medicine obtaining malpractice coverage for you at a rate acceptable to the School of Medicine. In the event that the School of Medicine cannot obtain malpractice insurance for you at a rate acceptable to the School, this offer is withdrawn. The School of Medicine will not provide tail coverage for any claims arising prior to and/or outside of employment with the School.

(iii) Maintaining hospital privileges at UMC.

(iv) Signing the enclosed Member Practice Agreement. The Member Practice Agreement states that as a member of the full-time faculty you will be a member of UHS i.e. the Faculty Practice Plan, and will see those patients for which the Plan has contracted. In addition, it provides guidance as to what constitutes practice income and has a non-solicitation clause.

(v) Timely completion of third party payor credentialing information and third party payor acceptance of you into their physician panels.

(vi) Confirmation that you (i) are not currently excluded, debarred, or otherwise ineligible to practice in the federal health care programs as defined in 42 USC 1320a-7b(f) (the “federal health care programs”); (ii) are not convicted of a criminal offense related to the provision of health care programs; and (iii) are not under investigation or otherwise aware of any circumstances which may result in your being excluded from participation in the federal health care programs.

Initial here _____
The Board of Regents of the Nevada System of Higher Education has declared mandatory unpaid leave (furlough) days for non-tenured faculty of one day a month for Fiscal Year 2011 (July 1, 2010 – June 30, 2011). This unpaid leave is equivalent to a 4.6% pay reduction.

You are entitled to enroll in the State of Nevada Public Employees comprehensive health insurance plan and will be required to participate in a mandatory retirement plan. You will be enrolled in the retirement plan alternative program (unless you were previously enrolled in the state of Nevada Public Employees Retirement System). You are required to contribute 11.25% of your salary to the plan and the university will provide a match of 11.25%.

As stated in the UNR Administrative Manual, Human Resources will attempt to verify academic credentials upon receipt of hiring documents. If the academic credentials cannot be verified, Human Resources will notify you that an official transcript of your highest degree must be submitted within thirty days of your first day of employment. Falsification or misrepresentation of credentials, or evidence that degrees offered in support of candidacy for employment have been issued from non-accredited institutions, shall invalidate the employment contract and shall be grounds for immediate termination.

This employment offer and your hiring are contingent upon you submitting original documents to verify your identity and eligibility to work in the United States, and on completing an I-9 Employment Verification Form as prescribed by federal law. Please be prepared to provide appropriate documentation as described on the enclosed I-9 Form to be completed on your first day of employment. Failure to provide appropriate documentation within three (3) business days of your start date will require that the University terminate your employment.

This offer letter is not a contract of employment and does not create a binding contract. This offer is subject to all of the terms, conditions and limitations contained in the Nevada System of Higher Education Code governing employment and requires the final approval of the appointing authority. A formal binding employment contract will be prepared and must be executed by both the appointee (you) and the appointing authority.

Benefits of this position include health, life and disability, and malpractice insurance. A summary of the benefits is enclosed with this offer letter.

Initial here ____
Any offer made to you verbally or in writing other than stated above is null and void. This offer will be withdrawn at 5:00pm PST on May 10, 2010. Please inform us of your decision concerning this offer by signing this letter and returning it by May 10, 2010 to Michelle Hogan 2040 W. Charleston Blvd., Suite 400, Las Vegas, NV 89102. You may return a copy by FAX to Michelle Hogan at (702) 671-6417.

If you have any questions about our offer or about any other aspects of the position, please contact either Dr. John Varras or Brian Walsh at (702) 671-2345.

Sincerely,

John Varras, M.D. Assistant Professor
Interim Chairman, Internal Medicine

Ole Thienhaus, M.D., M.B.A.
Dean, UNSOM

Marc Johnson, Ph.D.
Executive Vice President and Provost

Milton D. Glick, Ph.D.
President

I, Christian Stone, M.D., accept the terms and conditions contained in the conditional offer of employment and acknowledge that a formal employment contract must be executed by the University appointing authority to be binding.

______________________________  ______________________________
Signature                      Date

Enclosures: Physicians Medical Professional Liability
UNR Faculty Benefits Summary
Credentiaing Packet

(BOARD OF REGENTS' AGENDA 06/03/10 & 06/04/10) Ref. BOR-20, Page 7 of 26
May 4, 2010

Milton Glick, President
University of Reno
1664 N. Virginia
Mail Stop 0001
Reno, NV 89557

Dear President Glick:

In follow-up to your request, this letter will confirm salary support from UMC for GI services as follows:

$187,500 - Dr. Christian Stone
$187,500 - Dr. Tarek Ammar.

This support will be provided for the first year of each of these two physicians’ employment with the School of Medicine.

Please let me know if you need additional information.

Sincerely,

Kathleen Silver
Chief Executive Officer
Curriculum Vitae
February 2010

Personal Data

Name: Christian Diaz Stone
Business Address: Gastroenterology and Hepatology Institute of Nevada
2839 St. Rose Pkwy, Suite 130
Henderson, NV 89052
Phone: 702-558-4027
Fax: 702-558-4028
E-mail: cstonegin@lvcoxmail.com
Date of Birth: November 24, 1968
Place of Birth: Santiago, Chile
Citizenship: USA
Languages: Fluent in English, Spanish

Education

1990 B.A. University of California, Berkeley
1995 M.D. University of California, Irvine School of Medicine
2005 M.P.H. Master of Public Health, St. Louis University School of Public Health

Post-doctoral Training

1995-96 Internal Medicine Internship
Thomas Jefferson University, Philadelphia, PA
1996-98 Internal Medicine Residency
Thomas Jefferson University, Philadelphia, PA
1998-2001 Clinical Fellowship in Gastroenterology
Boston University School of Medicine, Boston, MA

Licensure and Certification

1995-98 Pennsylvania Medical License
1998-2001  Massachusetts Medical License #98774101
1998-2008  Diplomate, American Board of Internal Medicine #184143
2001-2009  Missouri Medical License #2001006565
2001-   Diplomate, Gastroenterology #184143
11/2009-  Nevada Medical License #13318

**Academic Appointments**

8/2001-6/2002  Instructor in Medicine (Gastroenterology)
Washington University in St. Louis School of Medicine,
St. Louis, MO

2002 - 2008  Assistant Professor of Medicine (Gastroenterology)
Washington University in St. Louis School of Medicine,
St. Louis, MO

11/2003-12/2004  Interim Director, Inflammatory Bowel Disease Program
Division of Gastroenterology, Washington University in St. Louis
School of Medicine, St. Louis, MO

1/2005-11/2009  Director, Inflammatory Bowel Disease Program
Division of Gastroenterology, Washington University in St. Louis
School of Medicine, St. Louis, MO

7/2008-11/2009  Associate Professor of Medicine (Gastroenterology)
Washington University in St. Louis School of Medicine,
St. Louis, MO

11/2009-  Clinical Associate Professor of Medicine
Division of Gastroenterology
University of Nevada, Las Vegas School of Medicine

**Hospital Appointments**

8/2001-6/2002  Staff Physician in Medicine, Barnes Jewish Hospital,
St. Louis, MO

2002 - 2008  Assistant Professor of Medicine, Barnes Jewish Hospital,
St. Louis, MO

7/2008-11/2009  Associate Professor of Medicine, Barnes Jewish Hospital,
St. Louis, MO

12/2009-  Staff Physician, Desert Springs Hospital
Las Vegas, NV

12/2009-  Staff Physician, St. Rose Dominican Hospital
Henderson, NV

Awards and Honors

1990  Graduation with High Honors, University of California, Berkeley

1991  Summer Research Fellowship, National Institutes of Health, Bethesda, MD

1999  Elected Participant in IBD Mentoring Program, Annenberg Foundation, Palm Desert, CA
1999  Participant in Live Therapeutic ERCP Workshop, Beth Israel Deaconess Medical Center, Boston, MA

2000  Recipient of Janssen Pharmaceuticals Gastroenterology Case Presentation Award, Boston, MA

2000  American College of Gastroenterology National Fellows Forum Abstract Platform Presenter, Carlsbad, CA

2000  Recipient of ACG Fellow’s Travel Award to 65th Annual Scientific Meeting, New York, NY

2000  Recipient of AGA Travel Grant to the World Congress of Gastroenterology, Bangkok, Thailand, 2002

2001  ACG North American Conference of Gastroenterology Fellows Poster Presenter

2001  Sixth Annual Young Investigators’ Conference in Digestive Diseases, Poster Presenter. Tampa, FL

2002  AGA Academic Skills Workshop selected participant. 9/27/02 Sarasota, FL

2005  CCFA IBD National Preceptorship Award: Mayo Clinic, Rochester, MN

2009  National Faculty Speaker, Centocor, Inc.
Editorial Responsibilities

2003-    American Board of Internal Medicine
          Relevance reviewer for Gastroenterology examination.

2008-    Editorial Board, World Journal of Gastroenterology

Ad hoc Reviewer

2004-    Inflammatory Bowel Diseases

2006-    Clinical Gastroenterology and Hepatology

2006-    Translational Research

2007-    Gut

2007-    Journal of Clinical Gastroenterology

2008-    Digestive Diseases and Sciences

2008-    Colorectal Disease

2008-    Nature Clinical Practice Gastroenterology and Hepatology

2009-    American Journal of Gastroenterology

2009-    American Journal of Case Reports

Major Committee Assignments

1997-98    Vice-President of House Staff, Thomas Jefferson University

6/2002-2004    AGA Committee on Trainees and Young Gastroenterologists

6/2003-5/2006    AGA Education Committee

2004-    Crohn’s and Colitis Foundation Medical Advisory Committee, Midwest Chapter.

2005-    Co-Chair, Career Advisory Program, AGA

2008 Co-Chair, Pan-American Conference of Gastroenterology/AGA, Santiago, Chile, November 2008.

2009- UCB Pharma Crohn’s Scholarship Selection Committee

Memberships in Professional Societies

1998- American Gastroenterological Association
1998- American College of Gastroenterology
1998-2003 American Society of Gastrointestinal Endoscopy
1998-2001 Massachusetts Medical Society, Delegate
2003- Crohn’s and Colitis Foundation of America, Mid-America Chapter

Teaching Experience

1991 Instructor, AIDS Outreach Program
University of California, Irvine, Irvine, CA

1999 Course Lecturer, Biology of Disease: Gastroenterology
Boston University School of Dentistry, Boston, MA

2000-1 Instructor, Student History and Physical Examination
Boston University School of Medicine, Boston, MA

2000-1 GI Consult Series Speaker, Wyeth-Ayerst Pharmaceuticals

2000-1 GI Speaker’s Program, AstraZeneca Pharmaceuticals

2001 Gastroenterology Division Rounds Conference 10/9/01
“Chronic Pancreatitis: Update on Pathogenesis”
Washington University in St. Louis School of Medicine

2001 Gastroenterology Division Core Clinical Conference 11/30/01
“Gut Neuroendocrine Tumors” WUSM

2002 Advances in Gastrointestinal Endoscopy 7/12/02
“Barrett’s Esophagus: Endoscopic Diagnosis and Staging”
Washington University in St. Louis School of Medicine

2002 Medical Grand Rounds, John Cochran VA Medical Center
“Barrett’s Esophagus: Review and Update”, St. Louis, MO, 8/21/02.

2002
Core Clinical Conference 12/13/02
Chronic Pancreatitis Board Review
Washington University in St. Louis School of Medicine

2002-
Internal Medicine Inpatient Attending Duties. Yearly teaching rounds (204 weeks) for medical team of residents and students.
Washington University in St. Louis School of Medicine

2003
Gastroenterology Division Rounds Conference 4/1/03
“Are we under-treating acute pancreatitis?” WUSM

2003
Advances in Gastrointestinal Endoscopy 4/11/03
“Histopathology of GERD and Barrett’s: a clinician’s perspective”
Washington University in St. Louis School of Medicine

2003
GI Pathophysiology Lecture to first year medical students 11/19/03
Acute and Chronic Pancreatitis
Washington University in St. Louis School of Medicine

2003
GI Core Clinical Conference 12/12/03
Neuroendocrine Tumors Board Review
Washington University in St. Louis School of Medicine

2004-
Review of Gastroenterology, yearly lecture
Washington University in St. Louis School of Physical Therapy

2004
“Practical aspects of acute pancreatitis” 4/14/04
Core Curriculum Conference, Washington U. School of Medicine

2004
“Top ten errors in IBD management” 7/21/04
GI Fellowship Core Curriculum, WUSM, St. Louis, MO.

2004/5
“Remicade revisited” 12/7/04 and 11/11/05
GI Grand Rounds, WUSM and Galaxy of Gastroenterology CME Program, St. Louis, MO

2006
“Update and current management of inflammatory bowel disease.”
Residents noon conference, WUSM, 5/3/06. St. Louis, MO.

2007
“Top ten errors in IBD management” 7/11/07
VAMC Medicine Grand Rounds, St. Louis, MO
2007  “The art of treating IBD: nuances that improve patient care”  
10/30/07, GI Grand Rounds, WUSM, St. Louis, MO

2/15/08, GI Division research lecture, WUSM, St. Louis, MO

2008  “Approach to medical management of the IBD patient”  
10/8/08, Medicine residents noon conference, WUSM, St. Louis, MO

2009  “IBD Evaluation and Management”  
2/4/09, Student Health Services, Washington University, St. Louis, MO

2009  “Unmet needs in IBD”  
2/4/09, Pfizer Pharmaceuticals, Chesterfield, MO.

2009  “Evaluation and approach to management of the hospitalized IBD patient.”  
2/10/09, Evening Grand Rounds, Department of Medicine, WUSM

2009  Resident’s noon conference, Barnes Jewish Hospital, “Approach to the management of the hospitalized IBD patient.” WUSM, St. Louis, MO, 8/17/09.

2010  Medical student noon conference lecture series, “Gastroenterology Myths”, UNLV School of Medicine, Las Vegas, NV, 1/13/10.

2010  Internal Medicine resident noon conference lecture, “Dysphagia and other esophageal disorders”, UNLV School of Medicine, Las Vegas, NV, 2/9/10.

Invited Lectures

2002  Clinical Problem-Solving Conference Discussant 5/3/02  
“A 36-year old man presents with nausea and vomiting”  
Washington University in St. Louis School of Medicine

2002  Galaxy of Gastroenterology II CME Program, St. Louis, MO 11/08  
“Practical aspects of acute pancreatitis”

2003  Clinical Problem-Solving Conference Discussant 3/21/03  
“A 39-year old woman with a history of PUD presents with epigastric pain, weight loss and diarrhea.” WUSM

2003  Clinical Problem-Solving Conference Discussant 11/7/03
“An 82-year old woman with 3 months of diarrhea and weight loss” Washington University in St. Louis School of Medicine

2004 Co-Chair, Inflammatory Bowel Diseases: A Combined Medical and Surgical Symposium. 9/18/04.

2004 Kansas City Southwest Missouri Clinical Society Fall Conference “What’s new in IBD” October 29, 2004

2004 Clinical Problem-Solving Conference Discussant 10/22/04 “A 32 year old man with nausea and epigastric pain” WUSM

2005 “Celiac disease: pathophysiology and diagnosis” 3/28/05 Department of Nutrition, WUSM

2005 “Current medical management of IBD” 11/3/05 Department of Colorectal Surgery, WUSM

2005 “Current medical management of IBD” 12/15/05; Rheumatology Grand Rounds, WUSM

2005 “Clinical trials and database tribulations” GI Grand Rounds, Wake Forest University, Winston-Salem, NC 12/20/05.

2006 “Update and new treatment options for inflammatory bowel disease.” Missouri Osteopathic Annual Convention, Branson, MO 4/27/06.

2006 Co-Chair, Investing in the Future - IBD Mentoring Symposium, DDW 2006, Los Angeles, CA


2006 Moderator, Pursuing a Career in Private Practice Symposium DDW May 21, 2006, Los Angeles, CA

2006 “Current medical management of IBD”, Medical Grand Rounds, VA Medical Center, St. Louis, MO 7/5/06.

2006 “IBD and C. difficile. Is there a relationship?” Yale School of Medicine, GI Research Conference, New Haven, CT 11/7/06.

2006
“Pathogenesis of IBD” and “Current management of Crohn’s disease”, guest lectures at Inflammatory Bowel Disease Conference, King Fahd Medical City, Riyadh, Saudi Arabia, 12/5/06.

2006
Co-Chair, Investing in the Future IBD Program, AGA, DDW Los Angeles, CA, May 2006

2007
“IBD and C. difficile. Is there a relationship?” Cedars-Sinai Medical Center, IBD Conference, Los Angeles, CA 2/19/07.

2007
Chair, Investing in the Future IBD Program, AGA, DDW Washington DC, May 2007

2008
“Pre- and post-operative management of the IBD patient.” Mississippi GI Society Annual Meeting, Jackson, MS, 2/9/08.

2008
“Clinical Research in Academic Gastroenterology”, Speaker, AGA Institute Committee Sponsored Symposium, Pursuing a successful career in academia. DDW 2008, 5/18/08.

2008
Chair, Clinical Symposium: Functional symptoms and stress in patients with IBD. DDW 2008, 5/21/08.

2008
“Building a successful IBD program” Speaker, Regional IBD Board Meeting, Nashville, TN, 7/25/08.

2008
“Management of complications of Crohn’s disease” and “IBD and colorectal cancer” Pan-American Congress of Gastroenterology, Santiago, Chile, 11/14/2008.

2008
Meet the Professor Luncheon. “Clostridium difficile”. Pan-American Congress of Gastroenterology, Santiago, Chile, 11/14/08.

2008
Moderator, “Intestinal Diseases Block” and “Inflammatory Bowel Disease Block”, Pan-American Congress of Gastroenterology, Santiago, Chile, 11/11 and 11/12, 2008.

2008
2009 Highlights of DDW 2009 CME Program “Inflammatory Bowel Disease”, Kansas City, MO, 6/16/09.

2009 Medical Grand Rounds, Christian Hospital, “The Hospitalized IBD patient: Special Topics Unique to this Population.” St. Louis, MO, 8/14/09.

2009 UCB Pharma Advisory Board Co-Chair/Moderator, Coronado, CA, 9/26/09.


2010 GI Grand Rounds, Challenging Case Series: IBD, Lackland Air Force Base, San Antonio, TX, 1/29/10


Previous Research Experience

1991 National Institutes of Health Summer Research Fellowship

1997 Thomas Jefferson University
    Project: Leptin receptor expression in the GI tract
    Preceptor: Robert Considine, Ph.D.

1998 University of Michigan
    Project: Treatment of H. pylori in Hanoi, Vietnam
    Preceptor: Keith Henley, M.D.

1998-2001 Boston Medical Center
    Project: The role of Gut-enriched Krüppel-like Factor (GKLF) in the pathogenesis of colon cancer
    Preceptor: Chi-Chuan Tseng, M.D., Ph.D.

2002-06 Fluid resuscitation in acute pancreatitis

2003-2004 ACT II trial: infliximab in ulcerative colitis


2005-6 Topical 10% metronidazole for perianal Crohn’s disease

2003-6 Sargramostim in Crohn’s Disease.
2006-7  C. difficile infection in IBD, incidence study.
2006-7  ACORDIS azathioprine dose-ranging study
2006-7  Visilizumab in ulcerative colitis

**Current Research**

2006-8  Efalizumab in Crohn’s disease
2006-  Topical tacrolimus for perianal Crohn’s disease
2007-  Crohn’s disease ileocolic resection: factors predicting recurrence
2007-  Risk factors for C. difficile infection in IBD
2008-  Arterial thrombotic events in IBD
2008-  Phase II, multi-dose, double-blind placebo-controlled, randomized, multi-center study of MDX1100 (anti-CXCL10 human monoclonal antibody) in subjects with active ulcerative colitis
2009-  Accutane and IBD: case-control study in pediatrics.
2009-  IBD and avascular necrosis incidence and steroid-related risks, in collaboration with St. Louis University SLUCore.

**Research Support**

Principal Investigator

2004-6  Mentors in Medicine Grant   PI
Oral glycine therapy in ulcerative colitis.   2 years, $8000.00

2005-8  Genentech, Inc.   PI
An open-label trial of efalizumab, a humanized anti-CD11a monoclonal antibody, in the treatment of moderate/severe Crohn’s disease.   1 year

2005-7  Mentors in Medicine Grant   PI
APOBEC-1 and COX-2 expression in colitis. 2 years, $8000.00

2006-8  TAP Pharmaceuticals   PI
Topical tacrolimus in perianal Crohn’s disease. 1 year, $4500.00
2007-8  Prometheus Laboratories  PI  
Serologies and risk of surgical recurrence in Crohn’s disease,  
1 year, $40,000.

Co-Investigator

CCFA 1903  Li (PI)  01/01/08-12/31/10
Molecular determinants of post-operative recurrence of Crohn’s disease  
Grant aims: (1) identify genetic and nongenetic factors associated with an altered risk of  
postoperative recurrence of CD after an ileocolic resection; (2) analyze the relationship between  
candidate genetic variants, ileal mucosal gene expression and post-operative recurrence of CD.

00434-0805-01  Dietz/Hunt (PI)  01/01/06-12/31/07  
Barnes-Jewish Hospital Foundation  
Gene Predictors of Early Postoperative Recurrence of Ileal Crohn’s Disease  
Grant aim: To determine whether CD susceptibility genes are predictive of early postoperative  
recurrence and to compare ileal gene expression in the resected and neo-terminal ileum.

WU Internal Competition  Li (PI)  04/01/07 – 03/31/08
Johnson and Johnson / Translational Research Seed Fund  
Molecular determinants of post-operative recurrence of Crohn’s disease  
The goal is to identify molecular determinants of recurrent Crohn’s disease by applying  
microarray technology to characterize mucosal gene expression profiles in biopsies of inflamed  
and un-inflamed biopsies of the ileum both at, and 6 months after, surgery. Results to be  
analyzed in relation to Crohn’s associated genotypes. Findings may allow for stratification of  
patients in future clinical trials using prophylactic infliximab for chemoprevention of post- 
operative recurrence of Crohn’s disease, and may lead to the identification of novel drug targets.

Bibliography

Selected Abstracts

HV Mao, BV Lak, T Long, NQ Chung, DM Thang, TV Hop, NN Chien, PQ Hoan, KS  
Henley, GI Perez-Perez, BA Connor, CD Stone, WD Chey. Omeprazole or ranitidine  
bismuth citrate triple therapy to treat Helicobacter pylori infection: A randomized,  
controlled trial in Vietnamese patients with duodenal ulcer. [Abstract of Distinction,  
DDW 1999]

Stone CD. A case of pheochromocytoma presenting as megacolon. American College of  
Gastroenterology 65th Annual Scientific Meeting, October 2000.

Stone CD and Tseng C-C. Gut-enriched Krüppel-like Factor mediates colonic cell  
growth through the APC/β-Catenin pathway. Evans Research Seminar, Boston Medical  
Center, Boston, MA, 2000.


Korzenik J, **Stone CD**, Valentine J, Hausman D, for the Leukine in Crohn’s Disease Study Group. Safety of repeated cycles of sargramostim in patients with moderately-to-severely active Crohn’s disease: experience from an open label extension trial. DDW 2004


Ha CY and **Stone CD**. An open label pilot study of topical 10% metronidazole ointment for refractory perianal Crohn's disease. WCOG 2005, poster #R0462

Sandborn WJ, **Stone CD**, Papdakis K, Valentine K, Ajayl FO, Nesbitt JD, Regall G. Assessment of systemic exposure following oral administration of mesalamine as an 800 mg tablet or 400 mg tablet: analysis of combined data from two randomized, double-blind, clinical trials in patients with ulcerative colitis. WCOG 2005, poster #R0472


Hong SS and **Stone CD**. Oral glycine improves symptoms in mild to moderate ulcerative colitis: an open-label pilot study. DDW 2006

Rodemann JF, Reske KA, Dubberke ER, and **Stone CD**. Increasing incidence of Clostridium difficile infection in patients with inflammatory bowel disease. DDW 2006

Oh YS, Seo DH, and **Stone CD**. Hemoconcentration is an independent risk factor for severe acute pancreatitis. DDW 2006

Anderson L, Unkart J, Cole EB, Li E, Miller C, Dietz DW, and Stone CD. ASCA positivity and smoking increase the risk for a second ileocolic resection in Crohn’s disease. DDW 2007


Stone CD, Accortt N, Magowan S. Prevalence of Clostridium difficile infection in patients with inflammatory bowel disease is significantly related with treatment modality. DDW 2010

Peer reviewed manuscripts

1. HV Mao, BV Lak, T Long, NQ Chung, DM Thang, TV Hop, NN Chien, PQ Hoan, KS Henley, GI Perez-Perez, BA Connor, CD Stone, WD Chey. Omeprazole or ranitidine bismuth citrate triple therapy to treat Helicobacter pylori infection: A randomized,


Invited publications


**Book chapters**

**Stone CD.** “Infections in Inflammatory Bowel Disease” in Inflammatory Bowel Disease Handbook, Lippincott Williams & Wilkins, Eds. Richard Bloomfeld and Stephen Bickston, 2010.


**Copyrights and Patents**

Naples Nephrology, P.A. Logo Design (copyrighted, State of Florida)

**Public Service**

KTVI FOX 2 News at 9 St. Louis: Interview on Capsule Endoscopy, aired 5/21/02.
KSDK NewsChannel 5 Cover Story: Screening Colonoscopy Interview, aired 12/17/02.
KTVI FOX 2 News St. Louis: Interview on Norwalk virus, aired 1/6/03.
BJC Today: Interview on irritable bowel syndrome and intestinal gas, published 3/10/03.
AGA Advocacy Day participant, 9/12/03.
CCFA Patient Information Symposium, Lecture “Do the labels UC and CD still work?” Missouri Baptist Medical Center, St. Louis, MO 2/21/04.
KTVI FOX 2 News St. Louis: Interview on epidemic diarrhea, aired 5/24/04
CCFA Roundtable for parents of adolescents with IBD. CCFA Gateway chapter office. St. Louis, MO 6/17/04.
CCFA Roundtable for adults with IBD. O’Fallon, MO 7/26/04.
AGA phone interview on the Career Advisory Program for DDW 2005. 3/14/05.
Riverfront Times phone interview on IBD. St. Louis, MO. Published 4/27/05.
LaDue News phone interview on IBD, St. Louis, MO 4/20/05.
Milwaukee Sentinel News, interview on Competitive Eating Contests, 8/25/05.
CCFA Annual Business Meeting Lecture. “Current trends in IBD clinical research” 9/20/05.
CCFA Patient Symposium Lecture: “Gateway to a cure: What’s new in IBD clinical trials” 2/25/06.
Barnes Jewish Hospital Outreach. Lecture on IBS and IBD, Carbondale, IL 11/2/06.
CCFA Midwest chapter Patient Symposium Lecture: “IBD vs. IBS. So what’s the difference?” 2/24/07.
GI and Hepatology News interview: “Picking a path: academics vs. private practice”. 6/30/08.
Keynote speaker, CCFA Patient Education Symposium, “Most common questions asked of the IBD doctor”, 2/21/09.
XM Radio Interview, ReachMD, “Inflammatory bowel disease and Clostridium difficile infection” 4/27/09.
Keynote Speaker, CCFA Patient Education Symposium, “Treating IBD: What we have learned from recent research and how your doctor decides on treatment”, Kansas City, MO, 10/10/09.
Keynote Speaker, Mercy Children’s Hospital, IBD Patient Symposium, “Recent Advancements in the Treatment of IBD”, Kansas City, MO, 10/24/09.